Bovine Blood Plasma Derivatives Sales

Bovine Blood Plasma Derivatives Sales Market Outlook

The global bovine blood plasma derivatives market is projected to reach approximately USD 5.8 billion by 2035, with a compound annual growth rate (CAGR) of around 7.1% during the period from 2025 to 2035. This growth is driven by the increasing demand for immunoglobulins in therapeutic applications, the rise in research activities in the fields of biopharmaceuticals and diagnostics, and an expanding market for innovative diagnostic tools that utilize these derivatives. Additionally, the growing prevalence of chronic diseases and the necessity for advanced therapeutics are propelling the demand for bovine blood plasma derivatives. The market is also benefiting from advancements in technology, which facilitate the efficient extraction and processing of plasma components.

Growth Factor of the Market

One of the primary growth factors for the bovine blood plasma derivatives market is the rising prevalence of autoimmune disorders and infections that require immunoglobulin therapy. As the incidence of such conditions continues to escalate, healthcare providers are increasingly relying on plasma-derived products to meet therapeutic needs. Additionally, the growing biopharmaceutical sector presents significant opportunities, as more companies focus on developing innovative therapies. Furthermore, the increased funding and investments in research related to plasma derivatives are fostering advancements in product development and effectiveness. The expanding geriatric population, who are more susceptible to various health issues, also contributes to the demand for effective therapeutic agents derived from bovine blood plasma. Moreover, the rise in awareness about the benefits of plasma products among healthcare professionals and patients is driving growth.

Key Highlights of the Market

• The market is expected to grow at a CAGR of 7.1% from 2025 to 2035.
• Immunoglobulins account for a significant share of the product type segment.
• Therapeutics are the leading application area within the market.
• North America dominates the market due to advanced healthcare infrastructure.
• Online pharmacies are emerging as a popular distribution channel.

By Product Type

Immunoglobulins:

Immunoglobulins are one of the most critical products derived from bovine blood plasma, primarily utilized for their therapeutic benefits in treating various diseases. They play a vital role in imparting immunity and are mainly administered to patients suffering from immune deficiencies or conditions affecting the immune system. The increasing prevalence of autoimmune diseases and the rising demand for effective treatment options are the driving forces behind the growth of this segment. The ability of immunoglobulins to enhance the immune response and provide passive immunity has garnered significant attention, leading to the expansion of research in this area. Additionally, the incorporation of advanced processing techniques ensures higher purity and efficacy of immunoglobulin products, further fuelling market growth.

Fibrinogen:

Fibrinogen derived from bovine blood plasma is essential for coagulation and wound healing, making it a crucial product in the medical field. This protein is utilized extensively in surgical procedures, particularly in cases of trauma and severe bleeding where rapid clot formation is necessary. The growing number of surgical operations and trauma cases is consequently driving the demand for fibrinogen products. Furthermore, advancements in extraction and purification methods are enhancing the quality and availability of fibrinogen, making it more commercially viable. As healthcare providers continue to seek effective solutions for managing bleeding disorders, fibrinogen's significance is expected to rise, positively impacting this segment's market growth.

Serum Albumin:

Serum albumin, another vital derivative from bovine blood plasma, is widely recognized for its role in maintaining oncotic pressure and transporting various substances in the blood. Its therapeutic applications include treating conditions such as shock, burns, and liver disease. As the demand for blood volume expanders and plasma substitutes increases, the serum albumin segment is poised for growth. The product's ability to stabilize patients in critical care settings enhances its value in modern medicine. Moreover, the ongoing research aimed at exploring additional applications of serum albumin is anticipated to open up new market opportunities. The trend towards using serum albumin in diverse healthcare applications underscores its importance and drives increased market participation.

Protease Inhibitors:

Protease inhibitors derived from bovine blood plasma play a significant role in various therapeutic interventions, particularly in managing viral infections and certain cancers. These inhibitors work by blocking protease enzymes, which are crucial for the replication of certain viruses and the progression of some cancers. As research continues to unveil the potential applications of protease inhibitors in innovative therapies, this segment is expected to witness considerable growth. The increasing global burden of viral diseases and the rising incidence of cancer are key factors contributing to the demand for these products. Furthermore, advancements in formulation and delivery systems are anticipated to enhance the effectiveness and reach of protease inhibitors in clinical applications.

Others:

The 'Others' segment encompasses various additional products derived from bovine blood plasma, including components such as clotting factors and growth factors. These products are utilized in specialized therapeutic applications and research settings. The growth of this segment is supported by the ongoing advancements in biotechnology and the exploration of novel applications for these products. As healthcare professionals and researchers seek innovative solutions for treating complex medical conditions, the demand for diverse plasma-derived products is expected to increase. This broadens the scope of the market, attracting new players and investment opportunities, thereby contributing to overall market growth.

By Application

Therapeutics:

The therapeutic application segment is a primary growth driver in the bovine blood plasma derivatives market, accounting for a significant share of the overall market. Products such as immunoglobulins and fibrinogen are indispensable in treating various health conditions, including immune deficiencies, trauma, and bleeding disorders. The growing prevalence of chronic diseases and the increasing number of surgical procedures are leading to an uptick in the demand for therapeutic plasma products. Furthermore, advancements in healthcare technologies and treatment protocols are enhancing the efficacy of these products, making them more appealing to healthcare providers. The increasing focus on personalized medicine and targeted therapies is also expected to further boost the therapeutic application of bovine blood plasma derivatives in the coming years.

Diagnostics:

The diagnostics application segment of the bovine blood plasma derivatives market is experiencing significant growth as well, driven by the rising need for accurate and timely diagnostic tools. Bovine blood plasma derivatives are utilized in various diagnostic assays and tests, aiding in the detection of diseases and conditions. The growing emphasis on early disease detection and preventive healthcare is propelling the demand for effective diagnostic solutions. Additionally, with the increasing adoption of advanced diagnostic technologies, such as ELISA and other immunoassays, the role of bovine blood plasma derivatives is becoming increasingly prominent. This trend is further supported by ongoing research and development activities aimed at enhancing the specificity and sensitivity of diagnostic assays, ultimately boosting the diagnostics segment's growth.

Research:

Research applications are a vital segment of the bovine blood plasma derivatives market, as these products are extensively used in laboratory studies and experiments. They play a crucial role in advancing scientific knowledge, particularly in areas such as immunology, biochemistry, and pharmacology. The demand for bovine blood plasma derivatives in research applications is being driven by the increasing number of research initiatives aimed at understanding diseases and developing novel therapeutic approaches. As funding for research continues to grow globally, the utilization of bovine blood plasma derivatives in various studies is expected to rise substantially. Furthermore, collaborations between research institutions and companies in the healthcare sector are enhancing the availability and application of these products in scientific investigation, further supporting market growth.

Others:

The 'Others' application segment includes a range of uses for bovine blood plasma derivatives that are not classified under therapeutics, diagnostics, or research. This may encompass applications in veterinary medicine, food processing, and cosmetic industries, where plasma derivatives are employed for their functional properties. The increasing recognition of the benefits of plasma-derived products in various industries is contributing to the growth of this segment. Additionally, ongoing innovations and the exploration of new applications for these products are expected to further expand the market opportunities within this segment. As demand for alternative uses of bovine blood plasma derivatives continues to grow, companies are likely to invest in research and development to tap into these emerging markets.

By Distribution Channel

Hospitals:

Hospitals serve as a major distribution channel for bovine blood plasma derivatives, particularly for therapeutic applications. These facilities require a consistent supply of high-quality plasma products to cater to the needs of patients requiring intravenous immunoglobulin therapy, blood volume expanders, and other treatments. The collaboration between hospitals and plasma collection centers is crucial for ensuring the availability of these products, which enhances patient care and treatment outcomes. The increasing number of surgeries and trauma cases, coupled with the growing patient population requiring plasma-derived therapies, solidifies hospitals' position as a prominent distribution channel in the market. Additionally, the integration of technology in hospital settings is improving inventory management and distribution efficiency, further supporting growth in this segment.

Clinics:

Clinics, including specialty clinics and outpatient facilities, are vital distribution channels for bovine blood plasma derivatives. These establishments often provide targeted care for specific health conditions, necessitating access to particular plasma products. The growing adoption of outpatient treatment models and the rising prevalence of chronic diseases are contributing to increased demand for plasma-derived products in clinics. Furthermore, as patients increasingly seek convenient healthcare options, clinics are expanding their offerings of therapeutic solutions, including immunoglobulins and other plasma derivatives. The emphasis on patient-centered care and personalized treatment plans is further driving the demand for bovine blood plasma derivatives within clinical settings.

Online Pharmacies:

Online pharmacies are emerging as a significant distribution channel for bovine blood plasma derivatives, catering to the increasing demand for convenient access to healthcare products. With the growing trend of digitalization in healthcare, patients are becoming more comfortable purchasing medical supplies and therapeutic products online. This shift is particularly beneficial for individuals requiring regular access to plasma-derived products, as it enhances convenience and ensures timely replenishment of necessary items. Additionally, the expansion of telemedicine and remote consultations is driving the growth of online pharmacies, as patients seek to obtain specific treatments without visiting healthcare facilities. The rise of e-commerce platforms dedicated to healthcare products is expected to further enhance the availability and accessibility of bovine blood plasma derivatives.

Others:

The 'Others' distribution channel segment encompasses various alternative channels through which bovine blood plasma derivatives are supplied to end-users. This may include distributors, wholesalers, and direct sales by manufacturers. These channels play a crucial role in ensuring that plasma-derived products reach a broader audience, particularly in regions where access to healthcare facilities may be limited. Moreover, partnerships with veterinary clinics and research institutions contribute to the availability of these products across different sectors. The increasing focus on supply chain efficiency and logistics optimization is expected to enhance the effectiveness of these distribution channels, providing further growth opportunities in the bovine blood plasma derivatives market.

By Ingredient Type

IgG:

IgG, or immunoglobulin G, is the most abundant type of antibody found in blood and extracellular fluid, and it plays a crucial role in the immune response. This ingredient type is predominantly utilized in therapeutic applications, particularly for patients with immune deficiencies. The growing demand for IgG in the treatment of various health conditions, including autoimmune diseases and infections, is driving the market for this ingredient type. The ability of IgG to neutralize pathogens and facilitate immune responses makes it an indispensable product in modern medicine. Additionally, advancements in extraction processes are enhancing the efficacy and purity of IgG products, further supporting its market growth.

IgM:

IgM, or immunoglobulin M, is another essential type of antibody that plays a critical role in the initial stages of immune response. Although it is less abundant than IgG, its significance in diagnosing and treating infections cannot be understated. The demand for IgM is driven by its application in diagnostic assays and therapeutic interventions, particularly for acute infections. The growing focus on early disease detection and the rising incidence of infectious diseases are fuelling the demand for IgM products. Furthermore, ongoing research into the potential therapeutic applications of IgM is expected to bolster this segment's growth, as healthcare providers seek innovative solutions for managing various health conditions.

IgA:

IgA, or immunoglobulin A, is an antibody that plays a crucial role in mucosal immunity, protecting mucosal surfaces from pathogens. Its importance in the gastrointestinal tract and respiratory system makes it a vital ingredient in various healthcare applications. The increasing awareness of gut health and the role of IgA in preventing infections is driving the demand for this ingredient type. Additionally, IgA is finding applications in supplement formulations aimed at enhancing immune function, further expanding its market reach. As research continues to explore the therapeutic potential of IgA in various health conditions, this segment is poised for growth in the coming years.

IgE:

IgE, or immunoglobulin E, is primarily associated with allergic reactions and responses to parasitic infections. Although it is present in smaller quantities compared to other immunoglobulins, its role in diagnosing and treating allergies is gaining recognition. The growing prevalence of allergic diseases worldwide is contributing to the demand for IgE-related products, particularly in diagnostic assays. As healthcare providers increasingly focus on understanding and managing allergies, the significance of IgE in clinical applications is expected to rise. Furthermore, ongoing research into the therapeutic potential of IgE targeting in various allergic conditions may lead to new market opportunities for this ingredient type in the future.

Others:

The 'Others' ingredient type segment encompasses various additional components derived from bovine blood plasma that are utilized for specific applications. This may include components like complement proteins and various growth factors. These ingredients are being explored for their therapeutic potential in different medical settings, including regenerative medicine and wound healing applications. The ongoing research into the efficacy and safety of these additional plasma-derived components is expected to enhance their market presence. As the healthcare industry continues to evolve, new applications for these products are likely to emerge, thereby contributing to the overall growth of the bovine blood plasma derivatives market.

By Region

Regional analysis of the bovine blood plasma derivatives market reveals distinct trends and growth patterns. North America is currently the largest market, driven by advanced healthcare infrastructure, a well-established pharmaceutical industry, and increasing investments in research and development. The U.S. alone is expected to account for nearly USD 2.8 billion by 2035, with a CAGR of 6.9% during the forecast period. The presence of key players and a supportive regulatory environment further bolster market growth in this region, making it a focal point for innovation and development in plasma-derived products.

Europe is another significant market for bovine blood plasma derivatives, with a projected value of approximately USD 1.6 billion by 2035. The region's strong emphasis on healthcare quality and patient safety, coupled with increasing research activities, supports market growth. The United Kingdom, Germany, and France are leading contributors to the European market, largely due to their advanced healthcare systems and high levels of healthcare spending. Asia Pacific is also emerging as a rapidly growing market, expected to witness a CAGR of 8.5%, driven by increasing healthcare expenditure and rising awareness regarding the benefits of plasma-derived products.

Opportunities

The bovine blood plasma derivatives market presents numerous opportunities for growth and expansion, particularly with the ongoing advancements in biotechnology and healthcare. One significant opportunity lies in the increasing demand for personalized medicine, where tailored therapies incorporating plasma-derived products can enhance patient outcomes. As healthcare systems increasingly focus on individualized treatment plans, companies that invest in research and development to create specialized plasma products will likely see substantial market benefits. Moreover, the growing emphasis on preventative care and early disease detection opens new avenues for diagnostic applications of bovine blood plasma derivatives, further driving demand and market growth.

Another opportunity is the rising interest in veterinary applications of bovine blood plasma derivatives. As the pet and livestock industries continue to grow, there is a corresponding demand for effective veterinary therapeutics and diagnostics. The utilization of plasma-derived products in treating animals is gaining traction, particularly in managing infections and promoting overall health. Companies that can successfully adapt their plasma processing techniques to cater to the veterinary market will likely tap into a lucrative segment. Additionally, collaboration with research institutions to explore innovative applications within both human and veterinary medicine can lead to breakthroughs that stimulate market growth, creating a win-win scenario for all stakeholders involved.

Threats

Despite the promising outlook for the bovine blood plasma derivatives market, several threats exist that could impede growth. One notable threat is the stringent regulatory environment governing the production and use of plasma-derived products. Compliance with regulations set by health authorities can be a complex and costly process for companies, particularly for smaller players. Additionally, any changes in regulatory policies or increased scrutiny regarding the safety and efficacy of these products can negatively impact market dynamics. Furthermore, the reliance on a specific source of raw materials, such as bovine blood, poses risks related to supply chain disruptions, disease outbreaks in cattle, and fluctuations in availability, which can affect production and pricing.

Another significant threat is the growing awareness and preference for alternative therapies, particularly with the rise of biopharmaceuticals and synthetic substitutes. As new treatments emerge that aim to replace or complement plasma-derived products, there may be a shift in market demand. Companies must be vigilant in monitoring trends and consumer preferences to remain competitive. Additionally, the threat of market saturation in certain regions, particularly where several players offer similar products, could lead to fierce competition and price wars, ultimately affecting profitability across the industry. To mitigate these threats, companies will need to invest in innovation, quality assurance, and strategic marketing to differentiate their offerings and maintain a strong presence in the market.

Competitor Outlook

• Grifols S.A.
• Octapharma AG
• CSL Limited
• Shire (now part of Takeda Pharmaceutical Company)
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Bio Products Laboratory Limited
• Hualan Biological Engineering Inc.
• Serum Institute of India Pvt. Ltd.
• LFB Group
• China Biologic Products Holdings, Inc.
• Sangamo Therapeutics, Inc.
• Biotest AG
• Kedrion S.p.A.
• Asahi Kasei Corporation

The competitive landscape of the bovine blood plasma derivatives market is characterized by a diverse array of players, ranging from established multinational corporations to emerging start-ups focused on innovative product development. The market is dominated by well-known companies such as Grifols S.A., CSL Limited, and Takeda Pharmaceutical Company, which possess significant market shares due to their comprehensive product portfolios and strong distribution networks. These companies invest heavily in research and development, ensuring that they stay at the forefront of innovation in plasma-derived therapies. Their established reputations, along with rigorous quality control measures, help maintain consumer trust and drive sales across various market segments.

Emerging players in the bovine blood plasma derivatives market are also making their mark by focusing on niche areas and unique formulations that meet specific consumer needs. Companies such as Hualan Biological Engineering Inc. and Kedrion S.p.A. are leveraging advancements in bioprocessing technologies to enhance product purity and efficacy, positioning themselves as viable alternatives to the larger competitors. Furthermore, collaborations and partnerships among these companies and research institutions are fostering innovation and accelerating product development, thereby expanding the competitive landscape. As new entrants continue to emerge, the competition will likely intensify, prompting established players to adopt innovative strategies to maintain their market positions.

Overall, the bovine blood plasma derivatives market is expected to remain highly competitive, with ongoing trends in consolidation, collaboration, and innovation shaping the future landscape. Companies that prioritize quality, invest in advanced processing technologies, and adapt to changing market demands are likely to thrive in this dynamic environment. Additionally, the pursuit of global expansion and diversification of product offerings will play a crucial role in maintaining a competitive edge. As the healthcare sector continues to evolve, the bovine blood plasma derivatives market will need to adapt to new challenges and opportunities, ensuring sustainability and growth in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 LFB Group
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Biotest AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CSL Limited
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Grifols S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Octapharma AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Kedrion S.p.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Asahi Kasei Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Sangamo Therapeutics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Thermo Fisher Scientific Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bio Products Laboratory Limited
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hualan Biological Engineering Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Serum Institute of India Pvt. Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Takeda Pharmaceutical Company Limited
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 China Biologic Products Holdings, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shire (now part of Takeda Pharmaceutical Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Bovine Blood Plasma Derivatives Sales Market, By Application
    • 6.1.1 Therapeutics
    • 6.1.2 Diagnostics
    • 6.1.3 Research
    • 6.1.4 Others
  • 6.2 Bovine Blood Plasma Derivatives Sales Market, By Product Type
    • 6.2.1 Immunoglobulins
    • 6.2.2 Fibrinogen
    • 6.2.3 Serum Albumin
    • 6.2.4 Protease Inhibitors
    • 6.2.5 Others
  • 6.3 Bovine Blood Plasma Derivatives Sales Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Clinics
    • 6.3.3 Online Pharmacies
    • 6.3.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Bovine Blood Plasma Derivatives Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Bovine Blood Plasma Derivatives Sales market is categorized based on

By Product Type

• Immunoglobulins
• Fibrinogen
• Serum Albumin
• Protease Inhibitors
• Others

By Application

• Therapeutics
• Diagnostics
• Research
• Others

By Distribution Channel

• Hospitals
• Clinics
• Online Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Grifols S.A.
• Octapharma AG
• CSL Limited
• Shire (now part of Takeda Pharmaceutical Company)
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Bio Products Laboratory Limited
• Hualan Biological Engineering Inc.
• Serum Institute of India Pvt. Ltd.
• LFB Group
• China Biologic Products Holdings, Inc.
• Sangamo Therapeutics, Inc.
• Biotest AG
• Kedrion S.p.A.
• Asahi Kasei Corporation